MedTrace Logo

Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.

NCT04951349 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2021-07-06

No results posted yet for this study

Summary

Phase 2b clinical trial to evaluate the safety and efficacy of intranasal application of GX-03 as a treatment and prevention for COVID-19.

Conditions

  • Covid19

Interventions

DRUG

GX-03

Same dosage used in Bactroban Nasal studies.

DRUG

Petrolatum ointment

Viscous ointment similar in form to study drug.

Sponsors & Collaborators

  • Gorgas Memorial Institute for Health Studies

    collaborator UNKNOWN

  • Hospital Santo Tomas

    collaborator OTHER

  • Hospital Modular - Covid-19

    collaborator UNKNOWN

  • Turn Therapeutics

    lead INDUSTRY

Principal Investigators

  • Julio Sandoval, MD · Medical Corps of Punta Pacifica Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-21
Primary Completion
2021-05-30
Completion
2021-05-30
FDA Drug
Yes

Countries

  • Panama

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04951349 on ClinicalTrials.gov